ABSTRACT
Sweet syndrome is a rare cutaneous condition with a broad clinical differential diagnosis. It can be classified into 3 subtypes: classic, malignancy-associated, and drug-induced. There are numerous associated disorders and provoking medications. Uncommonly, it can present as a multiorgan disease and cause significant morbidity. Systemic corticosteroids are the gold standard of treatment and yield rapid improvements in both lesions and symptoms. Nonsteroidal therapies may be effective alternatives, although high-quality comparative data are lacking. Some treatments for Sweet syndrome have paradoxically been implicated in the induction of disease.
Subject(s)
Dermatitis , Sweet Syndrome , Humans , Sweet Syndrome/diagnosis , Sweet Syndrome/drug therapy , Skin/pathology , Dermatitis/complications , Adrenal Cortex Hormones/therapeutic use , Diagnosis, DifferentialSubject(s)
Acitretin , Ichthyosis , Humans , Acitretin/therapeutic use , Methotrexate/therapeutic use , AcantholysisABSTRACT
Herpes zoster is caused by reactivation of the latent varicella zoster virus and often occurs in immunocompromised individuals. We describe a rare case of an immunocompetent patient with herpes zoster triggered by Shingrix, a non-live vaccine designed to protect against herpes zoster. Although herpes zoster has been described as a reaction to vaccinations before, to our knowledge this is the first report of herpes zoster triggered by a varicella zoster vaccine.
Subject(s)
Herpes Zoster , Herpesvirus 3, Human , Humans , Immunocompromised Host , Vaccination , Chickenpox VaccineABSTRACT
This case report describes a woman in her 50s with a large, crusted, erythematous plaque on the right chest that was consistent with a Hailey-Hailey disease flare.
Subject(s)
Pemphigus, Benign Familial , Humans , Cinacalcet/therapeutic use , Pemphigus, Benign Familial/diagnosis , Pemphigus, Benign Familial/drug therapy , Ointments , TacrolimusSubject(s)
Colitis, Ulcerative , Dermatology , Pyoderma Gangrenosum , Humans , Pyoderma Gangrenosum/diagnosis , Delphi Technique , ConsensusSubject(s)
COVID-19 , Dermatology , Dermatologists , Humans , SARS-CoV-2 , Surveys and QuestionnairesABSTRACT
BACKGROUND: While it is known that psoriasis patients have poor adherence to both topical and systemic medications, adherence to methotrexate is not well-characterized, and ways to improve methotrexate adherence have not been addressed. OBJECTIVE: The aim of this study was to evaluate whether a digital intervention improved adherence to oral methotrexate as measured by electronic monitoring. METHODS: Twenty-nine patients were randomized to receive either weekly digital interventions assessing treatment adherence or no intervention for 24 weeks. Patients received medication bottles with electronic monitoring, and returned at weeks 4, 12, and 24 to evaluate disease severity. RESULTS: The intervention group took methotrexate correctly 77.1% of the weeks observed compared to the control group which averaged 64.5%. More intervention patients took methotrexate as directed compared to the control group (78.3% vs 64.2%, p < 0.0001). Patients were most adherent around follow-up visits, with 100% of digital intervention patients and 80% of control patients taking methotrexate correctly during the week of a follow-up visit (p = 0.02). The digital intervention did not significantly improve disease severity in the intervention group compared to the nonintervention group. CONCLUSIONS: Low cost, scalable digital interventions may have the potential to increase psoriasis patient adherence to methotrexate, although the mechanism for the improvement is not yet well defined.
